🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

399 results for “Pari” Clear

  1. [18F]MNI-659

    Pari Pharma GmbH

    Patients with symptomatic and pre-symptomatic Huntington's disease

    phase 3 small molecule active

    1 trial

  2. [68Ga]Ga-PentixaFor

    Pari Pharma GmbH

    Primary aldosteronism, Primary aldosteronism

    phase 3 small molecule active

    1 trial

  3. cpFT

    Pari Pharma GmbH

    Infertility

    phase 3 small molecule active

    1 trial

  4. placebo of metformine, METFORMINE VIATRIS 500 mg, comprimé dispersible

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  5. -, RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome

    phase 2 small molecule active

    1 trial

  6. 11C-UCB-J, 18F-DPA-714, [11C]PiB

    Pari Pharma GmbH

    Alzeihmer disease

    phase 2 small molecule active

    1 trial

  7. A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  8. A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

    Fondazione Telethon ETS

    Ovarian cancer

    phase 2 other active

    1 trial

  9. ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  10. AMGLIDIA 6 mg/mL oral suspension

    Pari Pharma GmbH

    Transient hyperglycaemia in premature infants

    phase 2 small molecule active

    1 trial

  11. AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

  12. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  13. AZD9750, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  14. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    First Tracks Biotherapeutics

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  15. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial

  16. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  17. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial

  18. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  19. BARICITINIB

    Pari Pharma GmbH

    Juvenile Dermatomyositis

    phase 2 small molecule active

    1 trial

  20. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  21. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  22. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo of belimumab

    Pari Pharma GmbH

    Cryoglobulinemia vasculitis

    phase 2 small molecule active

    1 trial

  23. CARBOCAINE 20 mg/ml, solution injectable

    Pari Pharma GmbH

    Ischemic stroke

    phase 2 small molecule active

    1 trial

  24. CARBOPLATIN , ETOPOSIDE , ENZALUTAMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, MK-7684A, DOCETAXEL , Belzutifan, Lenvatinib, Lenvatinib, PREDNISONE , ABIRATERONE , DEXAMETHASONE , Olaparib

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources